Status:
UNKNOWN
Investigating the Diagnostic Potential of Tear Proteins in Cancer - A Pilot Study
Lead Sponsor:
Namida Lab
Collaborating Sponsors:
Arkansas Urology
CARTI
Conditions:
Breast Cancer
Ovarian Cancer
Eligibility:
All Genders
18-100 years
Brief Summary
This Pilot Study is to investigate the tear proteins in a multitude of cancer types and indulge in biomarker discovery to manufacture simple, accurate, and novel tear-based diagnostic tests.
Detailed Description
The Pilot Study is an observational study to investigate the diagnostic potential of tear proteins for Breast, Ovarian, Prostate, Melanoma, Pancreatic, and Colon cancer. In this pilot study, we use la...
Eligibility Criteria
Inclusion
- 18-100 years of age
- Presenting for the evaluation of an abnormal exam or test (mammogram, ultrasound, MRI, PET, etc.)
- Presenting for the evaluation of a palpable lump or mass
- Presenting with a mass may be pre or post-biopsy/diagnostic as long as there is a portion of the mass remaining.
- Have been diagnosed but have not received treatment
Exclusion
- Less than 18 years of age OR more than 100 years of age
- Concurrent eye infection or trauma
- Acute conjunctivitis
Key Trial Info
Start Date :
August 25 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2023
Estimated Enrollment :
500 Patients enrolled
Trial Details
Trial ID
NCT05223218
Start Date
August 25 2021
End Date
December 1 2023
Last Update
July 3 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Namida Lab
Fayetteville, Arkansas, United States, 72703